Medium-term impact of the SARS-CoV-2 mRNA vaccine against disease activity in patients with systemic lupus erythematosus
Objectives Numerous case reports have referred to new onset or flare of SLE after SARS-CoV-2 messenger RNA (mRNA) vaccines. Several observational studies showed that the short-term flare rate of SLE after SARS-CoV-2 vaccination is low. However, well-controlled clinical surveys are unavailable and th...
Main Authors: | , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2022-08-01
|
Series: | Lupus Science and Medicine |
Online Access: | https://lupus.bmj.com/content/9/1/e000727.full |
_version_ | 1818084659796377600 |
---|---|
author | Akira Onishi Hideaki Tsuji Shuji Akizuki Masao Tanaka Ryosuke Hiwa Ran Nakashima Hajime Yoshifuji Tsuneyasu Yoshida Yudai Takase Mirei Shirakashi Hideo Onizawa Koji Kitagori Akio Morinobu |
author_facet | Akira Onishi Hideaki Tsuji Shuji Akizuki Masao Tanaka Ryosuke Hiwa Ran Nakashima Hajime Yoshifuji Tsuneyasu Yoshida Yudai Takase Mirei Shirakashi Hideo Onizawa Koji Kitagori Akio Morinobu |
author_sort | Akira Onishi |
collection | DOAJ |
description | Objectives Numerous case reports have referred to new onset or flare of SLE after SARS-CoV-2 messenger RNA (mRNA) vaccines. Several observational studies showed that the short-term flare rate of SLE after SARS-CoV-2 vaccination is low. However, well-controlled clinical surveys are unavailable and the medium-term impact of the SARS-CoV-2 mRNA vaccines against the flare of SLE is uncertain. Therefore, we aimed to analyse the association between vaccination and medium-term subjective and objective disease activities of SLE and flares using matched pair methods.Methods Altogether, 150 patients with SLE from the Kyoto Lupus Cohort were included. Patients who received two doses of the SARS-CoV-2 mRNA vaccines were 1:1 matched with unvaccinated patients based on the first vaccination date. The outcome measures were the SLE Disease Activity Index-2000 (SLEDAI-2K), the Japanese version of the SLE Symptom Checklist Questionnaire (SSC-J) and the Safety of Estrogens in Lupus Erythematosus National Assessment-SLEDAI flare index at 30, 60 and 90 days after vaccination.Results SLEDAI-2K levels were not significantly different in vaccinated and unvaccinated patients with SLE at 30, 60 and 90 days after the second vaccination (adjusted estimate (95% CI): 30 days: −0.46 (−1.48 to 0.56), p=0.39; 60 days: 0.38 (−0.64 to 1.40), p=0.47; 90 days: 0.40 (−0.54 to 1.34), p=0.41). Similar results were observed in the SSC-J score (adjusted estimate (95% CI), 30 days: 0.05 (−1.46 to 1.56), p=0.95; 60 days: −0.63 (−2.08 to 0.82), p=0.40; 90 days: 0.27 (−1.04 to 1.58), p=0.69) and flare index (adjusted OR (95% CI), 30 days: 0.81 (0.36 to 1.85), p=0.62; 60 days: 1.13 (0.50 to 2.54), p=0.77; 90 days: 0.85 (0.32 to 2.26), p=0.74).Conclusion SARS-CoV-2 vaccination did not significantly influence the medium-term subjective and objective disease activities or flares of SLE until 90 days after the second vaccination. |
first_indexed | 2024-12-10T19:57:25Z |
format | Article |
id | doaj.art-26029197e0b9491799688df851338721 |
institution | Directory Open Access Journal |
issn | 2053-8790 |
language | English |
last_indexed | 2024-12-10T19:57:25Z |
publishDate | 2022-08-01 |
publisher | BMJ Publishing Group |
record_format | Article |
series | Lupus Science and Medicine |
spelling | doaj.art-26029197e0b9491799688df8513387212022-12-22T01:35:37ZengBMJ Publishing GroupLupus Science and Medicine2053-87902022-08-019110.1136/lupus-2022-000727Medium-term impact of the SARS-CoV-2 mRNA vaccine against disease activity in patients with systemic lupus erythematosusAkira Onishi0Hideaki Tsuji1Shuji Akizuki2Masao Tanaka3Ryosuke Hiwa4Ran Nakashima5Hajime Yoshifuji6Tsuneyasu Yoshida7Yudai Takase8Mirei Shirakashi9Hideo Onizawa10Koji Kitagori11Akio Morinobu124 Department of Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, Kobe, Japan1 Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Kyoto, Japan1 Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, JapanDepartment of Advanced Medicine for Rheumatic Diseases, Graduate School of Medicine, Kyoto University, Kyoto, Japan5 Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Kyoto, Japan5 Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Kyoto, Japan12Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Kyoto, JapanDepartment of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, JapanDepartment of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, JapanDepartment of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, JapanDepartment of Advanced Medicine for Rheumatic Diseases, Graduate School of Medicine, Kyoto University, Kyoto, JapanDepartment of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, JapanDepartment of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, JapanObjectives Numerous case reports have referred to new onset or flare of SLE after SARS-CoV-2 messenger RNA (mRNA) vaccines. Several observational studies showed that the short-term flare rate of SLE after SARS-CoV-2 vaccination is low. However, well-controlled clinical surveys are unavailable and the medium-term impact of the SARS-CoV-2 mRNA vaccines against the flare of SLE is uncertain. Therefore, we aimed to analyse the association between vaccination and medium-term subjective and objective disease activities of SLE and flares using matched pair methods.Methods Altogether, 150 patients with SLE from the Kyoto Lupus Cohort were included. Patients who received two doses of the SARS-CoV-2 mRNA vaccines were 1:1 matched with unvaccinated patients based on the first vaccination date. The outcome measures were the SLE Disease Activity Index-2000 (SLEDAI-2K), the Japanese version of the SLE Symptom Checklist Questionnaire (SSC-J) and the Safety of Estrogens in Lupus Erythematosus National Assessment-SLEDAI flare index at 30, 60 and 90 days after vaccination.Results SLEDAI-2K levels were not significantly different in vaccinated and unvaccinated patients with SLE at 30, 60 and 90 days after the second vaccination (adjusted estimate (95% CI): 30 days: −0.46 (−1.48 to 0.56), p=0.39; 60 days: 0.38 (−0.64 to 1.40), p=0.47; 90 days: 0.40 (−0.54 to 1.34), p=0.41). Similar results were observed in the SSC-J score (adjusted estimate (95% CI), 30 days: 0.05 (−1.46 to 1.56), p=0.95; 60 days: −0.63 (−2.08 to 0.82), p=0.40; 90 days: 0.27 (−1.04 to 1.58), p=0.69) and flare index (adjusted OR (95% CI), 30 days: 0.81 (0.36 to 1.85), p=0.62; 60 days: 1.13 (0.50 to 2.54), p=0.77; 90 days: 0.85 (0.32 to 2.26), p=0.74).Conclusion SARS-CoV-2 vaccination did not significantly influence the medium-term subjective and objective disease activities or flares of SLE until 90 days after the second vaccination.https://lupus.bmj.com/content/9/1/e000727.full |
spellingShingle | Akira Onishi Hideaki Tsuji Shuji Akizuki Masao Tanaka Ryosuke Hiwa Ran Nakashima Hajime Yoshifuji Tsuneyasu Yoshida Yudai Takase Mirei Shirakashi Hideo Onizawa Koji Kitagori Akio Morinobu Medium-term impact of the SARS-CoV-2 mRNA vaccine against disease activity in patients with systemic lupus erythematosus Lupus Science and Medicine |
title | Medium-term impact of the SARS-CoV-2 mRNA vaccine against disease activity in patients with systemic lupus erythematosus |
title_full | Medium-term impact of the SARS-CoV-2 mRNA vaccine against disease activity in patients with systemic lupus erythematosus |
title_fullStr | Medium-term impact of the SARS-CoV-2 mRNA vaccine against disease activity in patients with systemic lupus erythematosus |
title_full_unstemmed | Medium-term impact of the SARS-CoV-2 mRNA vaccine against disease activity in patients with systemic lupus erythematosus |
title_short | Medium-term impact of the SARS-CoV-2 mRNA vaccine against disease activity in patients with systemic lupus erythematosus |
title_sort | medium term impact of the sars cov 2 mrna vaccine against disease activity in patients with systemic lupus erythematosus |
url | https://lupus.bmj.com/content/9/1/e000727.full |
work_keys_str_mv | AT akiraonishi mediumtermimpactofthesarscov2mrnavaccineagainstdiseaseactivityinpatientswithsystemiclupuserythematosus AT hideakitsuji mediumtermimpactofthesarscov2mrnavaccineagainstdiseaseactivityinpatientswithsystemiclupuserythematosus AT shujiakizuki mediumtermimpactofthesarscov2mrnavaccineagainstdiseaseactivityinpatientswithsystemiclupuserythematosus AT masaotanaka mediumtermimpactofthesarscov2mrnavaccineagainstdiseaseactivityinpatientswithsystemiclupuserythematosus AT ryosukehiwa mediumtermimpactofthesarscov2mrnavaccineagainstdiseaseactivityinpatientswithsystemiclupuserythematosus AT rannakashima mediumtermimpactofthesarscov2mrnavaccineagainstdiseaseactivityinpatientswithsystemiclupuserythematosus AT hajimeyoshifuji mediumtermimpactofthesarscov2mrnavaccineagainstdiseaseactivityinpatientswithsystemiclupuserythematosus AT tsuneyasuyoshida mediumtermimpactofthesarscov2mrnavaccineagainstdiseaseactivityinpatientswithsystemiclupuserythematosus AT yudaitakase mediumtermimpactofthesarscov2mrnavaccineagainstdiseaseactivityinpatientswithsystemiclupuserythematosus AT mireishirakashi mediumtermimpactofthesarscov2mrnavaccineagainstdiseaseactivityinpatientswithsystemiclupuserythematosus AT hideoonizawa mediumtermimpactofthesarscov2mrnavaccineagainstdiseaseactivityinpatientswithsystemiclupuserythematosus AT kojikitagori mediumtermimpactofthesarscov2mrnavaccineagainstdiseaseactivityinpatientswithsystemiclupuserythematosus AT akiomorinobu mediumtermimpactofthesarscov2mrnavaccineagainstdiseaseactivityinpatientswithsystemiclupuserythematosus |